公开(公告)号：US20250163180A1

公开(公告)日：2025-05-22

申请号：US19034755

申请日：2025-01-23

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Hyejin CHUNG ,  Yeryoung YONG ,  Kyeongsu PARK ,  Eunyoung PARK ,  Ui-Jung JUNG ,  Yangsoon LEE ,  Eunjung KIM ,  Yong-Gyu SON ,  Wonjun SON ,  Seawon AHN ,  Donghoon YEOM ,  Chanmoo LEE ,  Junghyeon HONG ,  Moo Young SONG ,  Eun-Jung LEE ,  Na Rae LEE ,  Young Bong PARK ,  Eun-Jung LEE ,  Taewang KIM

IPC: C07K16/32 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

Abstract: Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US20190314452A1

公开(公告)日：2019-10-17

申请号：US16348249

申请日：2017-11-10

Applicant: YUHAN CORPORATION

Inventor： Han Na HONG ,  Jun Hwan KIM ,  Hyun Ho CHOI ,  Dohoon KIM ,  Taewang KIM ,  Se Woong OH ,  Moo Young SONG ,  Jong Gyun KIM

IPC: A61K38/18 ,  A61K38/26 ,  A61K38/17 ,  A61P1/16

Abstract: The present invention provides a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. Specifically, the present invention provides a fusion protein comprising a biologically active protein and an FGF21 mutant protein; and a pharmaceutical composition containing the fusion protein, which is effective for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. A pharmaceutical composition of the present invention has the effect of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used as a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.